The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...
Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...
The Washington Post on MSN13d
FDA approves a novel drug for schizophrenia, a potential ‘game changer’Even so, the arrival of Cobenfy offers a new tool for treating schizophrenia — a disease with profound societal consequences, ...
For the first time in nearly 30 years, the U.S. Food and Drug Administration has approved a new drug treating schizophrenia, ...
"Schizophrenia is a leading cause of disability worldwide ... People "are a little wary of claims before they actually see ...
Such is the case with newly approved Bristol-Myers Squibb drug Cobenfy. The underlying drug was first studied in Alzheimer’s ...
The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Doctors sometimes use lithium to treat schizophrenia. However, it is not a primary treatment method and evidence of its ...
For the first time in decades, the Food and Drug Administration has approved a new type of drug for schizophrenia. The twice-a-day pill to be marketed by Bristol Myers Squibb will be called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback